MNPR · Monopar Therapeutics Inc.

Current Thesis

Monopar Therapeutics’ ALXN1840 regulatory re-rating has lost its published price support; completing the application and securing acceptance for review would establish the next substantive regulatory progress. The adjusted market close of $96.47 on 2026-09-18 breached the weekly-close threshold below $100 published on 2026-09-05. That invalidation has occurred; a subsequent recovery would not erase it.

For the previously published price-supported filing leg, the narrative is dead — the 2026-09-18 weekly close broke its stated boundary. This is a structural assessment, not a finding that the drug has failed. Monopar announced the rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) on 2026-07-22, but its press-release index still ends at 2026-08-19 when checked on 2026-09-19; no completion announcement appears there. Monopar submission announcement, company release index.

Bullish and bearish views on Monopar Therapeutics Inc.

The model's bull view on Monopar Therapeutics Inc. (MNPR), in brief: The application process has begun. Monopar’s 2026-07-22 announcement states that the FDA authorized a rolling submission and that the first completed sections were submitted. This establishes an actual submission milestone, although it does not establish acceptance of the… The bear view: The published boundary has broken. The 2026-09-18 adjusted close of $96.47 is below the $100 weekly thesis-break threshold in the 2026-09-05 public dossier. The earlier structural case cannot be preserved by moving that threshold lower. Completion remains without a date. The… Both cases follow in full.

Bull Case

• The application process has begun. Monopar’s 2026-07-22 announcement states that the FDA authorized a rolling submission and that the first completed sections were submitted. This establishes an actual submission milestone, although it does not establish acceptance of the completed application. Company announcement.
• Reported funding supports continued development. The quarterly filing reports $134.3 million in cash, cash equivalents and investments at 2026-06-30. Management projected funding through at least 2027-12-31; that projection remains management’s estimate, rather than a guarantee against financing or development delays. Quarterly filing.

Bear Case

• The published boundary has broken. The 2026-09-18 adjusted close of $96.47 is below the $100 weekly thesis-break threshold in the 2026-09-05 public dossier. The earlier structural case cannot be preserved by moving that threshold lower.
• Completion remains without a date. The 2026-08-12 business update anticipated completion within the next few months, without specifying a calendar date. The company’s release index, checked on 2026-09-19, contains no subsequent completion announcement. Business update, release index.
• Filing acceptance is still unresolved. The quarterly filing for 2026-06-30 explicitly cautions that the FDA may neither accept the completed NDA for filing nor approve it. Authorization to submit sections does not settle either question. Quarterly filing.

Setup & Price Structure

Measured in the 2026-09-18 adjusted market snapshot, MNPR closed at $96.47, stood 22.1% below its $123.84 trailing annual high, and retained a three-month price gain of 40.5%. Its 14-period relative strength index (RSI) was 27.6. These observations document substantial recent weakness despite a positive three-month change; the RSI reading alone does not establish a reversal.

The dated positioning evidence is narrower than a crowding verdict. SEC Form 4 transactions previously reported by Investing.com and MarketBeat identify director sales by Raymond Anderson on 2026-08-25 and Kim Tsuchimoto on 2026-08-26. Those historical transactions do not establish continued selling in September. Current short interest, securities-borrow conditions, retail participation and a moving-average series are missing, so neither a squeeze claim nor a claim about distance above a rising average is supported.

Catalyst Calendar (next 30 days)

For 2026-09-19 through 2026-10-19, no company-confirmed dated catalyst was identified in the investor calendar or press-release index checked on 2026-09-19. Investor calendar, release index.

The decisive submission milestone remains undated: the 2026-08-12 update anticipated completion within the next few months. That wording does not support a specific October completion date or an FDA decision date. Business update.

What Would Change Our Mind

Loss of the published structural boundary has already settled the earlier price thesis: a weekly close below $100 occurred with the $96.47 close on 2026-09-18. The threshold remains the historical invalidation condition, rather than an untriggered future test.

Evidence for a separate recovery case would require an announced completed NDA, subsequent FDA acceptance for review, and a weekly market close back above the previously published $100 boundary. This is a conditional reassessment framework, not a recovery forecast. A refuse-to-file decision would defeat the filing-acceptance case; another weekly close below $100 would defeat any subsequently established recovery above that boundary.

Correlation Notes

This remains a single-company regulatory setup anchored to Monopar’s 2026-07-22 submission announcement. No paired biotechnology-index return series or comparable-company event sample accompanies the 2026-09-18 price snapshot. The evidence is insufficient to claim sector correlation, diversification benefits or a group-driven explanation for the decline. Submission announcement.